Imbruvica (ibrutinib) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has tried at least two systemic regimens (e.g., cladribine, pentostatin, rituximab, peginterferon alfa-2a, trametinib, dabrafenib, vemurafenib)

Reauthorization criteria

• Patient continues to meet initial criteria

Approval duration

1 year